These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 16706554)

  • 1. Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer.
    Wellington K; Keam SJ
    Drugs; 2006; 66(6):837-50. PubMed ID: 16706554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer.
    Wellington K; Keam SJ
    Drugs Aging; 2007; 24(2):169-71. PubMed ID: 17313204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme.
    Tyrrell CJ; Payne H; See WA; McLeod DG; Wirth MP; Iversen P; Armstrong J; Morris C;
    Radiother Oncol; 2005 Jul; 76(1):4-10. PubMed ID: 16145740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.
    See WA; Tyrrell CJ;
    J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S7-16. PubMed ID: 16896884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
    McLeod DG; Iversen P; See WA; Morris T; Armstrong J; Wirth MP;
    BJU Int; 2006 Feb; 97(2):247-54. PubMed ID: 16430622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development.
    Kolvenbag GJ; Blackledge GR; Gotting-Smith K
    Prostate; 1998 Jan; 34(1):61-72. PubMed ID: 9428389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years.
    Iversen P; McLeod DG; See WA; Morris T; Armstrong J; Wirth MP;
    BJU Int; 2010 Apr; 105(8):1074-81. PubMed ID: 22129214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.
    See WA; Wirth MP; McLeod DG; Iversen P; Klimberg I; Gleason D; Chodak G; Montie J; Tyrrell C; Wallace DM; Delaere KP; Vaage S; Tammela TL; Lukkarinen O; Persson BE; Carroll K; Kolvenbag GJ;
    J Urol; 2002 Aug; 168(2):429-35. PubMed ID: 12131282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
    Iversen P; Tyrrell CJ; Kaisary AV; Anderson JB; Van Poppel H; Tammela TL; Chamberlain M; Carroll K; Melezinek I
    J Urol; 2000 Nov; 164(5):1579-82. PubMed ID: 11025708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
    Tyrrell CJ; Iversen P; Tammela T; Anderson J; Björk T; Kaisary AV; Morris T
    BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
    Iversen P; Roder MA
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):361-9. PubMed ID: 18366284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bicalutamide: in early-stage prostate cancer.
    Carswell CI; Figgitt DP
    Drugs; 2002; 62(17):2471-79; discussion 2480-1. PubMed ID: 12421104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer.
    Kolvenbag GJ; Iversen P; Newling DW
    Urology; 2001 Aug; 58(2 Suppl 1):16-23. PubMed ID: 11502439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.
    Chodak G; Sharifi R; Kasimis B; Block NL; Macramalla E; Kennealey GT
    Urology; 1995 Dec; 46(6):849-55. PubMed ID: 7502428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of locally advanced prostate cancer--a new role for antiandrogen monotherapy?
    Abrahamsson PA
    Eur Urol; 2001; 39 Suppl 1():22-8. PubMed ID: 11114597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of bicalutamide in the treatment of prostate cancer.
    Schellhammer PF
    Expert Opin Pharmacother; 2002 Sep; 3(9):1313-28. PubMed ID: 12186624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of bicalutamide in the treatment of prostate cancer.
    Schellhammer PF; Davis JW
    Clin Prostate Cancer; 2004 Mar; 2(4):213-9. PubMed ID: 15072604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.
    Iversen P; Tyrrell CJ; Kaisary AV; Anderson JB; Baert L; Tammela T; Chamberlain M; Carroll K; Gotting-Smith K; Blackledge GR
    Urology; 1998 Mar; 51(3):389-96. PubMed ID: 9510340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bicalutamide in advanced prostate cancer. A review.
    Goa KL; Spencer CM
    Drugs Aging; 1998 May; 12(5):401-22. PubMed ID: 9606617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bicalutamide monotherapy for early stage prostate cancer: an update.
    Iversen P
    J Urol; 2003 Dec; 170(6 Pt 2):S48-52; discussion S52-4. PubMed ID: 14610410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.